📊 Popular Stock Analysis
My 2026 Watchlist: 3 Asymmetric Trades for the M&A Supercycle
Wed, Dec 17, 2025
Table of Contents
I usually avoid biotech. It’s too binary. You flip a coin, and either the drug works, or the stock goes to zero. I prefer predictable cash flow. But something weird is happening in the sector right now that forced me to look closer.
We are staring down the barrel of a massive "Patent Cliff." Starting late 2025, the biggest pharmaceutical companies in the world are going to lose exclusivity on their blockbuster drugs... we're talking about $200 billion in revenue evaporating. They have cash, but they don't have time. They can't wait five years for a science project to mature. They need revenue now.
That changes the math. The target isn't the company with the cool idea anymore; it's the company with the approved product and the messy chart. I went looking for the outliers... the companies that win regardless of the noise.
If you're new to my analysis process, I use a specific framework to filter noise... check out my 10x Stock Checklist: My Exact 47-Point Analysis Framework. It helps me strip away the narrative and focus on the solvency.
Here is what I found.
1. Lantheus Holdings (LNTH) - The Cash Cow
Everyone is looking for the cure for cancer. Lantheus just focuses on finding it. They are the leader in radiopharmaceuticals—specifically imaging agents. Their main product, PYLARIFY, lights up prostate cancer cells on scans so doctors can actually see what they are treating.
The moat here isn't just the chemical; it's the distribution. You can't just ship radioactive isotopes in a FedEx box. You need a specialized network, and Lantheus has it locked down. While the market is pricing this like a dying asset because of generic fears years down the road, the company is printing cash today.
- Price: ~$66
- Primary Product: PYLARIFY (Prostate Imaging)
- YoY Revenue Growth: ~14%
- Gross Margin: ~60-65%
- Cash Runway: Infinite (They are profitable)
The financials looked good, but I had to be sure. So I ran it through my 10x Stock Checklist: My Exact 47-Point Analysis Framework... and it passed the "Management Integrity" check with flying colors. The downside seems capped by their current cash flow, which is rare in this sector.
2. TransMedics Group (TMDX) - The Logistics Monopoly
This is the risky one. But the logic is undeniable. For decades, if you donated a heart or liver, they threw it in a glorified ice cooler. It damaged the organ and limited how far it could travel. TransMedics changed that. They built a portable machine that keeps the heart beating and warm during transport.
They aren't just selling the machine anymore; they are becoming a logistics airline. They bought their own planes. They manage the retrieval. They own the network. The CEO just bought about $3 million worth of stock recently. When insiders buy at all-time highs, I pay attention.
I don't trust the numbers blindly. I pull up the chart on TradingView to check the Volume Profile. If you aren't using their advanced charts yet, you should... it saves me hours of headaches. I set my indicators to the Weekly view to see the bigger picture. Specifically, I look at the RSI... if it's below 30, I'm interested.
If you want to find other stocks like this, use the TradingView Screener and filter for "Market Cap < 2B" and "Rel Vol > 2". It's the easiest way to spot momentum before the news does.
- Price: ~$126
- Primary Product: Organ Care System (OCS)
- YoY Revenue Growth: ~32%
- Insider Activity: CEO bought ~$3M in Q3
- Risk: Execution. Running an airline is hard.
3. Twist Bioscience (TWST) - The Infrastructure
I call this the "Pick and Shovel" play. Twist doesn't try to cure diseases. They manufacture the synthetic DNA that other companies need to do their research. They figured out how to print DNA on silicon chips, which makes it cheaper and faster than anyone else.
They are the Intel of biology. Whether the drug works or fails, the research lab still needs to buy DNA from Twist. The stock has been beaten down because they burn cash, but they are guiding for profitability in 2026. That is a major psychological shift for the market.
- Price: ~$31
- Primary Product: Express Genes (Synthetic DNA)
- YoY Revenue Growth: ~17-20%
- Gross Margin: 53.4% (and expanding)
- Catalyst: Hitting EBITDA breakeven in late 2026.
The Reality Check (Risks)
I want to be clear... I could be wrong.
Biotech is brutal. Lantheus faces a patent cliff of its own eventually. TransMedics could fail at managing a fleet of airplanes and blow up their margins. Twist could miss their profitability target and get crushed by dilution. These aren't savings accounts.
My Plan
I am looking to enter Lantheus (LNTH) first. The valuation is just too low to ignore, and it provides a buffer. I'm waiting for TransMedics (TMDX) to cool off slightly before adding, but the insider buying is keeping my finger near the buy button.
Investing in small caps is a minefield. If you want to see exactly how I vet these companies to avoid zeroes, grab my 10x Stock Checklist: My Exact 47-Point Analysis Framework. It helps me stay objective when the hype gets loud.
Conclusion
We are heading into a heavy M&A cycle. Big Pharma needs revenue, and these three companies have it. I'm betting on the businesses that sell the tools and the clear winners, not the science experiments.
Before you open a position, make sure it passes your own sniff test. Download my 10x Stock Checklist to run the full audit.
Not financial advice, just sharing my thoughts!